PharmaCielo Beheer

Beheer criteriumcontroles 2/4

PharmaCielo's CEO is Marc Lustig, appointed in Jul 2023, has a tenure of 1.33 years. directly owns 3.86% of the company’s shares, worth CA$622.69K. The average tenure of the management team and the board of directors is 2.3 years and 5.6 years respectively.

Belangrijke informatie

Marc Lustig

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.3yrs
Eigendom CEO	3.9%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

CEO

Marc Lustig (50 yo)

1.3yrs

Tenure

CA$57,500

Compensatie

Mr. Marc Lustig, M. Sc., M. B.A., had been an Executive Chairman at IM Cannabis Corp. since December 29, 2020 and had been its Director since October 11, 2019 until June 05, 2024. He has been Chairman and...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Marc Lustig	Chairman & CEO	1.3yrs	CA$57.50k	3.86% CA$ 622.7k
Ian Atacan	CFO, Corporate Secretary & Director	3.4yrs	CA$275.00k	0.36% CA$ 58.5k
Andres Botero	Chief Operating Officer	no data	CA$290.57k	geen gegevens
Decio de Castro Filho	Chief Medical Officer	2.3yrs	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

Ervaren management: PCLO's management team is considered experienced (2.3 years average tenure).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Marc Lustig	Chairman & CEO	4yrs	CA$57.50k	3.86% CA$ 622.7k
Ian Atacan	CFO, Corporate Secretary & Director	2.3yrs	CA$275.00k	0.36% CA$ 58.5k
Anders Milton	Member of Medical & Scientific Advisory Board	8yrs	geen gegevens	geen gegevens
Douglas Bache	Independent Director	5.8yrs	CA$60.00k	0.041% CA$ 6.7k
Riccardo Polosa	Member of Medical & Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
Nadia Crosignani	Member of Medical & Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
Konstantinos Farsalinos	Member of Medical & Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
Gerard Madlambayan	Member of Medical & Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
Solomon Rataemane	Member of Medical & Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
David Richardson	Member of Medical & Scientific Advisory Board	5.6yrs	geen gegevens	geen gegevens
William Petron	Lead Independent Director	3.4yrs	CA$541.68k	2.6% CA$ 419.2k

5.6yrs

Gemiddelde duur

Ervaren bestuur: PCLO's board of directors are considered experienced (5.6 years average tenure).

PharmaCielo Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024

Pharmacielo Ltd. Appoints Marc Lustig as CEO

CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock.

Independent Lead Director recently bought CA$83k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.023 loss in 2Q 2023)

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding

PharmaCielo Ltd. announced that it expects to receive CAD 2 million in funding

PharmaCielo Ltd., Annual General Meeting, Feb 20, 2024

Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.034 loss in 3Q 2022)

PharmaCielo Ltd. announced that it has received CAD 4.78 million in funding

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

New major risk - Financial position

Second quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.023 loss in 2Q 2022)

Pharmacielo Ltd. Appoints Marc Lustig as CEO

PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding

CEO, President & Chairman of the Board exercised options to buy CA$33k worth of stock.

New minor risk - Share price stability

First quarter 2023 earnings released: CA$0.023 loss per share (vs CA$0.019 loss in 1Q 2022)

Full year 2022 earnings released: CA$0.096 loss per share (vs CA$0.18 loss in FY 2021)

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Independent Lead Director recently bought CA$83k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.034 loss per share (vs CA$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.023 loss per share (vs CA$0.049 loss in 2Q 2021)

PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Less than half of directors are independent

PharmaCielo Ltd. Announces Board and Executive Changes

CEO, President & Chairman of the Board recently bought CA$67k worth of stock

PharmaCielo Ltd., Annual General Meeting, Sep 01, 2022

CEO, President & Chairman of the Board exercised options to buy CA$87k worth of stock.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Full year 2021 earnings: Revenues miss analyst expectations

High number of new directors

Independent Lead Director recently bought CA$92k worth of stock

Independent Lead Director recently bought CA$292k worth of stock

PharmaCielo Ltd. announced that it expects to receive CAD 15 million in funding

Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Third quarter 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Lead Director recently bought CA$1.8m worth of stock

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

CEO, President & Director Henning von Koss has left the company

Pharmacielo Ltd. Provides Revenue Guidance for the Second Half of 2021

Second quarter 2021 earnings released

Independent Chairman of the Board Simon Langelier has left the company

Chief Financial Officer Scott Laitinen has left the company

First quarter 2021 earnings released: CA$0.047 loss per share (vs CA$0.064 loss in 1Q 2020)

Is PharmaCielo (CVE:PCLO) A Risky Investment?

Independent Director recently bought CA$115k worth of stock

Third quarter 2020 earnings released: CA$0.083 loss per share (vs CA$0.04 loss in 3Q 2019)

PharmaCielo Delivers First Commercial Shipment of THC-Free Broad-Spectrum Distillate

Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

New 90-day high: CA$2.68

PharmaCielo Provides Update on GMP Compliance Process

PharmaCielo Ltd. Announces the Appointment of Caroline Lenardon for Expansion of Retail Investor Relations Capacity

CEO, President & Director recently sold CA$88k worth of stock

New 90-day high: CA$2.18

PharmaCielo Ltd., PharmaCielo Colombia Holdings S.A.S. Enter into Strategic Alliance with AssuredTrans Inc

Revenue and earnings miss expectations

Pharmacielo Ltd. Announces Step Down of David Attard as Board Member, Effective December 1, 2020

PharmaCielo Ltd. Delivers Its First Commercial Shipment of Medicinal Grade CBD Isolate

New 90-day high: CA$0.74

PharmaCielo Ltd. Announces the First Harvest Cycle of Six High-THC Cultivars

PharmaCielo Ltd. announced that it expects to receive CAD 5 million in funding

PharmaCielo Ltd. Appoints Marc Lustig as Lead Director

PharmaCielo Ltd. Expands Portfolio of Cannabis Extracts to Meet Global B2b Medical-Grade Market Demand

New 90-day low: CA$0.54

New 90-day low - CA$0.55

CEO

Tenure